Supplementary Table 2. Baseline characteristics of metformin users and non-users before propensity score matching in women

Variable	Women		p value
	Metformin users (n = 8,040)	Metformin non-users (n = 2,192)	
Age group (yr)			< 0.01
18–24	10 (0.1)	2 (0.1)	
25–34	62 (0.8)	20 (0.9)	
35–44	243 (3.0)	53 (2.4)	
45–54	673 (8.4)	115 (5.3)	
55–64	1,162 (14.5)	215 (9.8)	
65–74	2,300 (28.6)	541 (24.7)	
> 75	3,590 (44.7)	1,246 (56.8)	
Age (yr)	73 (63–79)	76 (69–81)	< 0.01
Region, metropolitan	3,179 (39.5)	886 (40.4)	0.456
Nationality, Korean	7,983 (99.3)	2,183 (99.6)	0.122
Household income			0.274
0 (lowest)	906 (11.3)	284 (13.0)	
1	1,297 (16.1)	338 (15.4)	
2	917 (11.4)	233 (10.6)	
3	1,122 (14.0)	294 (13.4)	
4	1,452 (18.1)	390 (17.8)	
5 (highest)	2,346 (29.2)	653 (29.8)	
Disability			< 0.01
No	6,717 (83.5)	1,711 (78.1)	
Physical disability	1,297 (16.1)	462 (21.1)	
Internal disability	26 (0.3)	19 (0.9)	
Lesion site of TB			0.035
Pulmonary	6,886 (85.6)	1,838 (83.9)	
Extra-pulmonary	1,154 (14.4)	354 (16.1)	
TB history			0.501
New case	7,397 (92.0)	2,007 (91.6)	
Previously treated TB	643 (8.0)	185 (8.4)	
PPM hospital	5,985 (74.4)	1,676 (76.5)	0.053
AFB smear positivity	2,880 (35.8)	744 (33.9)	0.265
Culture positivity	3,933 (48.9)	1,004 (45.8)	0.031
Charlson Comorbidity Index			< 0.01
0	2,002 (24.9)	469 (21.4)	
1	3,789 (47.1)	891 (40.7)	
2	568 (7.1)	201 (9.2)	
≥ 3	1,681 (20.9)	631 (28.8)	
Comorbidity			
Transplantation	12 (0.2)	15 (0.7)	< 0.01
HIV	1 (0.0)	0 (0.0)	0.602
Cancer	168 (2.1)	54 (2.5)	0.287

Supplementary Table 2. Continued

Variable	Women		p value
	Metformin users (n = 8,040)	Metformin non-users (n = 2,192)	
Notification year			< 0.01
2011	991 (12.3)	351 (16.0)	
2012	1,164 (14.5)	306 (14.0)	
2013	1,086 (13.5)	253 (11.5)	
2014	1,227 (15.3)	340 (15.5)	
2015	1,164 (14.5)	315 (14.4)	
2016	1,219 (15.2)	304 (13.9)	
2017	1,189 (14.8)	323 (14.7)	
Anti-diabetic treatment			
Sulfonylurea	4,339 (54.0)	1,318 (60.1)	< 0.01
Insulin	297 (3.7)	207 (9.4)	< 0.01
Other DM medication[a]	4,795 (59.6)	1,387 (63.3)	0.002
Follow-up duration (d)	212 (183–284)	213 (182–287)	0.24
Treatment outcome			< 0.01
Treatment success/failure	7,367 (91.6)	1,881 (85.8)	
Death due to all causes	673 (8.4)	311 (14.2)	
Cause of death			0.96
TB-related deaths	129 (1.6)	60 (2.7)	
Non-TB-related deaths	544 (6.8)	251 (11.5)	

Values are presented as number (%) or median (interquartile range).

AFB, acid-fast bacilli; DM, diabetes mellitus; HIV, human immunodeficiency virus; PPM, public-private mix; TB, tuberculosis.

[a]Other DM medications include dipeptidyl peptidase–4 inhibitors, glinide, thiazolidinedione, glucagon-like peptide-1, alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors.